Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
|
|
- Myron Simpson
- 5 years ago
- Views:
Transcription
1 Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013
2 Systemic therapy for NSCLC in 2013 (What you should know) Evolution of chemotherapy and targeted agents in advanced lung cancer Adjuvant chemotherapy in resectable stage I III Chemotherapy in unresectable stage III
3 Cancer Incidence in Thailand 2008 Population (Millions) Total 65 Males 32 Females 33 Source: US Census Bureau, International Data Base Females Males Liver Liver Breast Cancer Site Colon and Rectum Urinary bladder Uterine Cervix Colon and Rectum Incidence, Prevalence, Mortality, and Mortality-to-Incidence Ratios for Common Cancers in Males and Females Long and Bronchus Non-Hodgkin Lymphoma Lung and Bronchus Age-Standardized Rate per 100, Incidence Number of New Cases of Cancer 10,195 6,429 2,744 1,195 1,336 6,243 4,995 5,282 3,026 2,108 Rate per 100,000 (not agestandardized) Year Prevalence Number of Persons Living with Cancer 4,984 4,875 6,488 3,283 2,681 19,846 2,390 19,096 2,412 5,147 Mortality Age-Standardized Rate per 100, Mortality-to- Incidence Ratio MR:IR Age-standardized to the World Standard Population. Source: GLOBOCAN 2002, IARC. US Census Bureau International Data Base country population for 2002 used as weights for prevalence rates Pfizer Inc. All rights reserved.
4
5 Advanced NSCLC: what are our treatment goals for patients? Longer life increased overall survival Better life symptom improvement prolonged time to progression improved disease control rate reduced toxicity improved quality of life (QoL)
6 Significant milestones in lung cancer therapy Survival (%) Supportive care + CT Supportive care Time from randomisation (months) 1990s Meta-analyses confirm survival benefit with chemotherapy in advanced NSCLC NSCLC Collaborative Group. BMJ 1995;311: Results shown for cisplatin-based regimens only (11 trials)
7 Significant milestones in lung cancer therapy 12 Median survival (months) BSC 2 4 months Cisplatinbased regimens: 6 8 months Platinumbased doublets (3G): 8 10 months Bevacizumab/ Cetuximab + platinum-based doublet: >12 months s 1980s
8 First-Line Therapy Platinum-Based Regimens in stage IV NSCLC Summary of conventional doublets Column A: Cisplatin Carboplatin Column B: Paclitaxel Docetaxel Gemcitabine Pemetrexed* Irinotecan Vinorelbine Etoposide Column C: Bevacizumab Cetuximab Doublets Regimen: Choose I from each column * Non-squamous histology
9
10 Pac Paclitxel; G gemcitabine; Vin vinorelbine; Doc docetaxel
11 Treatment Options for Advanced NSCLC (The Evolution) 1 st line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib EGFR TKI : inhibitors of Tyrosine kinase domain epidermal growth factor receptor Gefetinib, Erlotinib
12 Treatment Options for Advanced NSCLC (The recent Paradigm) 1 st line Maintenance Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed +Bevacizumab +Cetuximab 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib EGFR TKI : inhibitors of Tyrosine kinase domain epidermal growth factor receptor Gefetinib, Erlotinib Cetuximab monoclonal antibody to extracellular domain of EFGR Bevacizumab monoclonal antibody to vascular endothelial growth factor (VEGF)
13 Treatment Options for Advanced NSCLC (The recent Paradigm) 1 st line Maintenance 2 nd line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine +Bevacizumab Platinum + docetaxel +Cetuximab Platinum + vinorelbine Platinum + pemetrexed Not reimburse in Thailand!! Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib Required authorization
14 Treatment Options for Advanced NSCLC (The Real world) 1 st line Standard platinum based regimens Platinum + paclitaxel Platinum + gemcitabine Platinum + docetaxel Platinum + vinorelbine Platinum + pemetrexed 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib 3+ line Erlotinib/ Gefitinib Required authorization
15 Treatment Options for Advanced NSCLC (The Very Real world) 1 st line Standard platinum based regimens Platinum + paclitaxel 2 nd line Docetaxel Required authorization
16
17 Important considerations for optimising outcomes when selecting therapy for NSCLC Molecular markers (EGFR, ALK) IHC Histology Squamous (1/3 patients) FISH Squamous-cell carcinoma PCR Non-squamous (2/3 patients) EGFR epidermal growth factor receptor ALK anaplastic lymphoma kinase Adenocarcinoma Large-cell carcinoma
18 Cetuximab (Erbitux) The EGFR/HER Family Trastuzumab (Herceptin) TGFα EGF Ligand binding domain Epi β-cel (-) HB-EGF Amp (-) HRG (NRG1) Epi HB-GF NRG1 NRG2 NRG3 NRG4 Transmembrane Tyrosine kinase domain (-) erb-b1 EGFR HER1 neu Erb-b2 HER2 Erb-b3 HER3 Erb-b4 HER4 Gefitinib (Iressa) Erlotinib (Tarceva) Lapatinib (Tykerb)
19 Common clinical characteristics of NSCLC patients with EGFR mutations Ethnicity: Asian Wildtype Mut+ Wild type Mut+ Smoking history: never smoker Gender: female Mut+ Wildtype Wildtype Mut+ Histology: adenocarcinoma 60% of all EGFR mutation-positive Retrospective review of 2,880 cases Mitsudomi, et al. Int J Clin Oncol 2006 patients Mok, et al. NEJM 2009
20 Any Factor to Consider When Treatment NSCLC Histology is increasingly important when making treatment decisions for advanced NSCLC Pemetrexed is more effective in non-squamous histology Bevacizumab is more toxic in squamous histology Molecular marker now guides treatment decisions in specific groups of patients patients with EGFR mutation-positive disease gain more benefit from EGFR TKIs (Gefetinib, erlotinib) than chemotherapy in both first and second line patients with rearrangements of the anaplastic lymphoma kinase (ALK) gene gain more benefit from ALK TKI (crizotinib) than chemotherapy in second line therapy
21 EGFR TKI as first-line treatment for patients with EGFR mutation positive advanced NSCLC EGFR TKI Gefetinib, Erlotinib, Afatinib [TITLE]
22 Why EGFR TKI in first-line treatment? A EGFR Act MUT+ NSCLC First-line EGFR TKI PD PD Second-line chemotherapy (3rd line) Death B First-line chemotherapy PD Second-line EGFR TKI PD (3 rd line) Death C D First-line EGFR TKI PD First-line Rapid chemotherapy worsening PD Rapid worsening Death Death Patients who receive only one line of therapy Theoretical survival Gridelli, et al. Lung Cancer 2011
23 Important considerations for optimising outcomes when selecting therapy for NSCLC Molecular markers (EGFR, ALK) Histology Squamous (1/3 patients) Issue of testing in Thailand Availability of test Availbility of drugs Turn around time Reimbursement Squamous-cell carcinoma Non-squamous (2/3 patients) PCR Adenocarcinoma Large-cell carcinoma
24 EGFR TKI as first-line treatment for patients with EGFR mutation positive advanced NSCLC Study Chemo. PFS (Hazard Ratio) OS (hazard Ratio) IPASS Carboplatin/Paclitaxel X 6 cycles VS Gefetinib 0.48 ( ), p < NS WJTOG3405 Cisplatin/Docetaxel X 3-6 cycles VS Gefetinib ( ), p < NS NEJSG 002 Carboplatin/Paclitaxel > 3 cycles Vs Gefetinib 0.30 ( ), p < NS OPTIMAL Carboplatin/Gemcitabine X 4 cycles VS Erlotinib HR=0.16 ( ) Log-rank p< NS EURTAC Chemotherapy HR 0 37 ( ) NR VS Erlotinib ; p< Mok TS, et al. N Engl J Med 2009, Mitsudomi T, et al. Lancet Oncol 2010, Maemondo M, et al. N Engl J Med 2010., Zhou, et al. Lancet Oncol 2011; Rosell, et al. Lancet Oncol 2012
25 Treatment Options for Advanced NSCLC carbo + paclitaxel (+ BV or Ctux) Standard platinum cisplatin + gemcitabine (+ BV or Ctux) based carboplatin + docetaxel (+ Ctux) regimens Maintenance cisplatin + vinorelbine (+ Ctux) therapy Not reimburse in Thailand!! 1 st line 2 nd line Docetaxel /Pemetrexed Erlotinib/ Gefitinib Not reimburse In Thailand!! 3+ line Erlotinib/ Gefitinib Required authorization
26
27 Updates in Community Oncology 2011: A Focus on Non-Small-Cell Lung Cancer Chemotherapy Today and the Need for Targeted Therapies The choice of treatment depends upon the histologic subtype, molecular abnormalities, general medical condition. Doublet chemotherapy for 4-6 cycles is standard (good PS) Targeted drugs can add to doublet chemotherapy Bevacizumab and cetuximab with survival benefit Targeted agents where target is known can replace firstline chemotherapy (EGFR-TKI in EGFR mutants) Most patients eventually progress and require additional therapy. Maintenance therapy improves survival Second-line therapy improves survival
28 Updates in Community Oncology 2011: A Focus on Non-Small-Cell Lung Cancer Lung Cancer Molecular Consortium Analysis in Lung Adenocarcinomas No Mutation Detected KRAS 22% AKT1 NRAS MEK1 MET AMP HER2 PIK3CA 2% BRAF 2% Double Mutants 3% EML4-AKL 7% EGFR 17% Mutations found in 54% (280/516) of tumors completely tested (95% CI: 50% to 59%) Kris MG, et al. ASCO CRA7506. Johnson BE, et al. IASLC WCLC Abstract O16.01
29 NSCLC Meta-analysis of Cisplatin Containing Regimens in Adjuvant Lung Cancer 8 cisplatin-based trials examined (n = 1394) Patients randomized to surgery alone or surgery + adjuvant chemotherapy 13% reduction in risk of death with surgery + adjuvant chemotherapy vs surgery alone (P =.08) Non-Small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:
30 Major Changes in New Staging Classification T and M Descriptors N0 N1 N2 N3 6th Edition TNM 7th Edition TNM Stage Stage Stage Stage T1 ( 3 cm) T1a ( 2 cm) IA IIA IIIA IIIB T1b (> 2-3 cm) IA IIA IIIA IIIB T2a (> 3-5 cm) IB IIA (IIB) IIIA IIIB T2 (> 3 cm) T2b (> 5-7 cm) IIA (IB) IIB IIIA IIIB T3 (> 7 cm) IIB (IB) IIIA (IIB) IIIA IIIB T3 invasion T3 IIB IIIA IIIA IIIB T4 (same lobe nodules) T3 IIB (IIIB) IIIA (IIIB) IIIA (IIIB) IIIB T4 (extension) T4 IIIA (IIIB) IIIA (IIIB) IIIB IIIB M1 (ipsilateral lung) T4 IIIA (IV) IIIA (IV) IIIB (IV) IIIB (IV) T4 (pleural effusion) M1a IV (IIIB) IV (IIIB) IV (IIIB) IV (IIIB) M1 (contralateral lung) M1a IV IV IV IV M1 (distant) M1b IV IV IV IV Goldstraw P, et al. J Thorac Oncol. 2007;2: IASLC staging handbook in thoracic oncology. Orange Park, Fl: Editorial Rx Press; 2009.
31 Positive Adjuvant NSCLC Studies Since 1995 Meta-analysis Study Rx n 5-Yr OS, % HR IALT [1] IB-IIIA CALGB [2] IB JBR.10 [3] IB-II ANITA [4,5] IB, II, IIIA Surgery Cis + VP16/vinca Surgery Carbo/paclitaxel Surgery Cis/vinorelbine Surgery Cis/vinorelbine Arriagada R, et al. N Engl J Med. 2004;350: Strauss GM, et al. J Clin Oncol. 2008;26: Winton T, et al. N Engl J Med. 2005;352: Douillard JY, et al. Lancet Oncol. 2006;7: Douillard JY, et al. ASCO Abstract 7013.
32 LACE Meta-analysis of Adjuvant Chemotherapy : Adjuvant Chemotherapy: Is It for Everyone? Category No. Deaths/ No. Patients HR for OS (Chemo vs Control) HR (95% CI) Stage IA 104/ ( ) Stage IB 515/ ( ) Stage II 893/1616 Test for trend: P = ( ) Stage III 878/ ( ) Chemotherapy Better Control Better Chemotherapy may be detrimental for stage IA, but stage IA patients were generally not given the potentially best combination cisplatin + vinorelbine (13% of stage IA patients vs 43% for other stages) Pignon JP, et al. J Clin Oncol. 2008;26:
33 Adjuvant Chemotherapy : What Lessons Have We Learned For whom : Stage II-IIIA IB? Not for IA Which Agents Platinum agents important : cisplatin Not enough data available on carboplatin Vinorelbine effective Not enough data on other drugs with appropriate dose of cisplatin
34 Phase III NATCH Study: Post-op chemo vs Pre-op chemo vs Surgery Alone Untreated patients with resectable stage IA (T > 2 cm), IB, II and T3N1 NSCLC (N = 624) Stratified by tumor size (< 3 vs 3-5 vs > 5 cm) and age ( 60 vs > 60 yrs) Paclitaxel 200 mg/m 2 + Carboplatin AUC 6 every 3 wks for 3 cycles (n = 201) Surgery (n = 212) Surgery (n = 181) Primary endpoint: 5-yr DFS Secondary endpoints: toxicity, OS, biomarker analysis Surgery (n = 211) Paclitaxel 200 mg/m 2 + Carboplatin AUC 6 every 3 wks for 3 cycles (n = 139) Felip E, et al. J Clin Oncol. 2010;28:
35 Adjuvant vs Preop Chemotherapy vs Surgery Alone: NATCH Phase III Results Treatment Arm Surgery alone Chemo surgery Surgery chemo Outcome 5-Yr DFS, % 5-Yr OS, % Median OS,Mos More patients in preoperative chemotherapy arm received treatment Similar resectability rates, surgical procedures, postoperative mortality across arms Felip E, et al. J Clin Oncol. 2010;28: Felip E, et al. ASCO Abstract 7500.
36 NATCH: Clinical Stages of Patients on Enrollment Clinical Stage, % Preop Chemotherapy (n = 199) Surgery Alone (n = 210) Adjuvant Chemotherapy (n = 210) T1N T2N T1N T2N T3N T3N T4N0* *Patient not eligible. Felip E, et al. J Clin Oncol. 2010;28:
37 Phase III Targeted Therapy Adjuvant Trials Trial Stage Therapy Target N Primary Endpoint JBR.19 [1] IB-IIIA Gefitinib x 2 yrs RADIANT [2] I-IIIA Erlotinib x 2 yrs MAGRIT [3] IB-IIIA Vaccine x 27 mos E1505 [4] IB ( 4 cm)- IIIA Chemo ± bevacizumab EGFR- IHC+ 503 OS 945 DFS MAGE-A DFS 1500 OS 1. Goss GD, et al. ASCO Abstract LBA ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT ClinicalTrials.gov. NCT
38 Management of stage III non-small cell lung cancer Resected stage IIIA disease Adjuvant chemotherapy with a cisplatin-based doublet Post-op RT : N2, margin+/uncertain,? LN sampling Unresected stage III disease : +N2 or N3 documented prior to definitive treatment (Induction chemo ) Concurrent chemoradiotherapy with a platinum-based doublet ( consolidation chemo) Sequential chemotherapy followed by definitive RT RT alone? Surgery after induction Chemo or Chemo-RT.
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationFirst line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?
Perspective First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die? Jared Weiss Multidisciplinary Thoracic Oncology Program, Lineberger
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationREVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok
Personalized medicine in lung cancer: what we need to know Tony S. K. Mok Abstract Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationAdjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Editorial Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine Peng Shen 1, Wenzhao Zhong 2 1 Department of Oncology, Nanfang Hospital, Southern Medical
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationSlide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
More informationAdditional clinical features of this patient include:
*Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationcontinuing education Non-small cell lung cancer: Molecular targets and emerging options for care Daniel Morgensztern, MD
continuing education educational objectives After participating in this activity, clinicians should be better able to Perform diagnostic/molecular testing (EGFR, KRAS, EML4-ALK) for NSCLC according to
More informationEGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationAdjuvant Therapies for Lung Cancers: New Directions
Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationSystemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and the Lung Cancer Disease Site Group
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment for Patients with Advanced Non-Small Cell Lung Cancer P.M. Ellis, E.T. Vella, Y.C. Ung and
More informationIndividualized therapy in lung cancer Where are we in 2012?
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More information